Australia Health

Anteris Technologies Global (ASX:AVR) announced plans for a proposed US$200 million underwritten public offering of common stock.

Telix Pharmaceuticals (ASX:TLX) reported strong commercial and operational performance for the quarter ended Dec. 31, 2025, achieving its upgraded full-year FY25 revenue guidance with unaudited group revenue of approximately US$804 million.

Cambium Bio (ASX:CMB), a clinical-stage regenerative medicine company specialising in ophthalmology and tissue repair, has secured a $2.4 million strategic investment from its major shareholder, Zheng Yang Biomedical Technology.

Cancer diagnostics company Pacific Edge (ASX:PEB) has released its investor update for the three months ended December 2025.

Telix Pharmaceuticals (ASX:TLX) announced that China's National Medical Products Administration has accepted its New Drug Application for TLX591-Px .

Immuron (ASX:IMC), an Australian-based biopharmaceutical company, has announced continued unaudited sales growth for Travelan, its over-the-counter immune supplement targeting pathogenic bacteria in the gastrointestinal tract.

Mesoblast (ASX:MSB), a leader in allogeneic cellular medicines, reported that the US Food & Drug Administration has acknowledged that data from the company's first Phase 3 trial of rexlemestrocel-L for chronic discogenic low back pain favour the therapy in reducing pain intensity.

PolyNovo (ASX:PNV) reported unaudited trading results for the first half of FY26, with group revenue rising 26% to $68.2 million, compared with $54.1 million in the same period last year.

Zelira Therapeutics (ASX:ZLD) has secured US$33 million (before costs) through a strategic fundraising with TGC Biotechnology Fund, into its HOPE 1 special purpose vehicle, bringing total equity raised to US$36.6 million.

Vitasora Health (ASX:VHL) has completed its $11 million capital raise, following the full receipt of a $6.8 million cornerstone investment at a placement price of $0.03 per share.

Sonic Healthcare's (ASX:SHL) new CEO, Jim Newcombe, is facing investor pressure to reconsider the company’s US operations as he steps into the shoes of long-serving predecessor Colin Goldschmidt.

Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX), a global leader in 3D-printed biomimetic and bioresorbable implants, has entered a multi-year exclusive agreement with Majeton to commercialise its dental, orthodontic, and maxillofacial products across China, Hong Kong, and Macau.